Sign In
Buy TEM
$50.56
-1.76 (-3.36%)
At Close: Jun 16, 2026
How TEM Is Capitalizing on AI-Driven Pathology Market Growth
10:41am, Monday, 26'th Jan 2026
Tempus AI boosts AI pathology reach by acquiring Paige and launching Paige Predict to deliver biomarker insights across 16 cancer types.
Tempus AI: Staying Bullish On Leading Healthcare AI Play
09:44am, Friday, 23'rd Jan 2026
Tempus AI (TEM) remains a resilient healthcare AI leader, with proprietary data driving traction and a clear buy opportunity amid recent volatility. TEM reported preliminary 2025 revenue of ~$1.27B (+
Cathie Wood Loads Up On This Robotaxi Stock, Ark Dumps Roku In Latest Trades
09:06pm, Thursday, 22'nd Jan 2026
On Thursday, Jan. 22, 2026, Cathie Wood-led Ark Invest bought $2.4 million in Tempus AI and WeRide while selling $1.6 million in Roku amid mixed analyst signals.
HIMS vs. TEM: Which Health-Tech Stock Looks More Compelling?
01:45pm, Thursday, 22'nd Jan 2026
Hims & Hers and Tempus AI are transforming digital health in distinct ways, but which platform looks more compelling right now? Let's dive in.
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
09:50am, Thursday, 22'nd Jan 2026
Ark Invest is beating the market again in 2026, and the iconic growth investor wants to keep it that way.
Tempus AI Highlights Strong Growth At The J.P. Morgan Healthcare Conference
08:00am, Thursday, 22'nd Jan 2026
Tempus AI is reaffirmed as a Strong Buy, with profitability arriving a year earlier than consensus, driven by robust revenue growth and successful Ambry Genetics integration. TEM is guided to $1.59B r
Cathie Wood Doubles Down On Netflix Despite Weak Guidance, Ark Invest Dumps This Social Media Stock
09:06pm, Wednesday, 21'st Jan 2026
On Wednesday, Jan. 21, 2026, Cathie Wood-led Ark Invest bought $7.11 million in Netflix shares, but sold shares of Pinterest.
Canton Hathaway, LLC Buys 1,170 Shares of Tempus AI Inc (TEM)
06:10pm, Wednesday, 21'st Jan 2026
Summary Canton Hathaway, LLC raised its stake in Tempus AI Inc (TEM) by 135.1%, purchasing 1,170 shares to own 2,036 shares valued at about $120,230 as
Tempus AI's Key 2025 Milestones Continue to Gain Industry Attention
09:06am, Wednesday, 21'st Jan 2026
TEM hits $1.1B TCV, signs 70+ pharma data deals and posts its first positive adjusted EBITDA in Q3 2025 as adoption accelerates.
Tempus Announces the Launch of Paige Predict
08:30am, Wednesday, 21'st Jan 2026
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the launch of Paige Predict, a suite of cutting-
Cathie Wood's Ark Invest unveiled its "big ideas" for 2025 in a cryptic list, challenging users to interpret a series of custom images called "ARKmoji" to understand their picks for the year.
TEM's Collab for Oncology Patient Population Is Gaining Attention
08:31am, Tuesday, 13'th Jan 2026
Tempus AI's partnerships with NYU Langone and Northwestern Medicine aim to expand genomic testing and data-driven cancer care.
Why Tempus AI Stock Rose Today
07:07pm, Monday, 12'th Jan 2026
Healthcare leaders are partnering with Tempus AI to bolster their development pipelines. Tempus' sales are expanding at a rapid pace.
Tempus AI, Inc. (TEM) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
07:05pm, Monday, 12'th Jan 2026
Tempus AI, Inc. (TEM) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Why Tempus AI Stock Is Trading Higher On Monday?
02:53pm, Monday, 12'th Jan 2026
Tempus AI partners with NYU Langone Health and Northwestern Medicine to broaden access to genomic testing, enhancing precision oncology and individualized patient care.
